Below are the most recent publications written about "Coronary Restenosis" by people in Profiles.
-
Olier I, Sirker A, Hildick-Smith DJR, Kinnaird T, Ludman P, de Belder MA, Baumbach A, Byrne J, Rashid M, Curzen N, Mamas MA. Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention. Heart. 2018 10; 104(20):1683-1690.
-
Noman A, Balasubramaniam K, Alhous MHA, Lee K, Jesudason P, Rashid M, Mamas MA, Zaman AG. Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitus. Catheter Cardiovasc Interv. 2017 Jun 01; 89(7):1195-1204.
-
Mehanna E, Attizzani GF, Nakamura D, Nishino S, Fares A, Aoun R, Costa MA, Bezerra HG. Impact of Neointimal Calcifications on Acute Stent Performance during the Treatment of In-Stent Restenosis. Arq Bras Cardiol. 2016 May; 106(5):419-21.
-
Farooq V, Mamas MA, Fraser DG, El-Omar M, Clarke B, Fath-Ordoubadi F. Serial optical coherence tomography of drug-eluting stent in-stent restenosis treated with the Absorb bioresorbable scaffold: an effective treatment? EuroIntervention. 2015 Mar 22; 10(11):e1.
-
Fanari Z, Weiss SA, Zhang W, Sonnad SS, Weintraub WS. Comparison of percutaneous coronary intervention with drug eluting stents versus coronary artery bypass grafting in patients with multivessel coronary artery disease: Meta-analysis of six randomized controlled trials. Cardiovasc Revasc Med. 2015 Mar; 16(2):70-7.
-
Mamas MA, Foin N, Abunassar C, Khan MA, Di Mario C, Fraser DG. Stent fracture: Insights on mechanisms, treatments, and outcomes from the food and drug administration manufacturer and user facility device experience database. Catheter Cardiovasc Interv. 2014 Jun 01; 83(7):E251-9.
-
van der Veer EP, de Bruin RG, Kraaijeveld AO, de Vries MR, Bot I, Pera T, Segers FM, Trompet S, van Gils JM, Roeten MK, Beckers CM, van Santbrink PJ, Janssen A, van Solingen C, Swildens J, de Boer HC, Peters EA, Bijkerk R, Rousch M, Doop M, Kuiper J, Schalij MJ, van der Wal AC, Richard S, van Berkel TJ, Pickering JG, Hiemstra PS, Goumans MJ, Rabelink TJ, de Vries AA, Quax PH, Jukema JW, Biessen EA, van Zonneveld AJ. Quaking, an RNA-binding protein, is a critical regulator of vascular smooth muscle cell phenotype. Circ Res. 2013 Oct 12; 113(9):1065-75.
-
Waseda K, Hasegawa T, Ako J, Honda Y, Grube E, Whitbourn R, Ormiston J, O'Shaughnessy CD, Henry TD, Overlie P, Schwartz LB, Sudhir K, Chevalier B, Gray WA, Yeung AC, Fitzgerald PJ. Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: pooled IVUS results from the ZoMaxx I and II trials. Circ J. 2010 Nov; 74(11):2334-9.
-
Contractor H, Mamas M, Fraser DG. Angiographic time course of in-stent restenosis with zotarolimus drug-eluting stents. Can J Cardiol. 2008 Jul; 24(7):e45.
-
Zhou RH, Pesant S, Cohn HI, Eckhart AD. Enhanced sterol response element-binding protein in postintervention restenotic blood vessels plays an important role in vascular smooth muscle proliferation. Life Sci. 2008 Jan 16; 82(3-4):174-81.